期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血小板膜GPⅡb/Ⅲa基因多态性与冠心病 被引量：3

Platelet Membrane Glycoprotein Ⅱb/Ⅲa Genetic Polymorphisms and Coronary Heart Disease
下载PDF
导出
摘要 血小板膜GPⅡb/Ⅲa的基因多态性能够通过影响血小板的功能,进而在冠心病的发病以及治疗中的阿司匹林抵抗、二磷酸腺苷受体拮抗剂疗法中发挥作用。但它是否为冠心病独立的危险因子尚有争议,2者之间的关系以及机制的阐明将有可能为冠心病的防治提供崭新的思路与策略。 Platelet membrane glycoprotein Ⅱb/Ⅲa genetic polymorphisms can effect the function of platelet,and play an important role in the pathogenesis and treatment of coronary heart disease.Whether GPⅡb/Ⅲa genetic polymorphisms is an independent risk factor for coronary heart disease is uncertain.To explore the relationship between them may be helpful for diagnosis and treatment of coronary heart disease.
作者 苏冠华 王朝晖
机构地区 华中科技大学同济医学院附属协和医院心内科
出处 《心血管病学进展》 CAS 2006年第z1期14-16,共3页 Advances in Cardiovascular Diseases
关键词 血小板膜糖蛋白 基因多态性 阿司匹林抵抗 冠心病 platelet membrane glycoprotein genetic polymorphisms aspirin resistance coronary heart disease
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献18

  • 1[1]Kunicki TJ,Newman PJ.The molecular biology of human platelet proteins[J].Blood,1992,80:1386-1404.
  • 2[2]Taylor DW,Barnett HJ,Haynes RB,et al.Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy:A randomized controlled trial.ASA and Carotid Endarterectomy (ACE) Trial Collaborators[J].Lancet,1999,353(9171):2179-2184.
  • 3[3]Mikkelsson J,Perola M,Penttila A,et al.The GPⅢa (beta3 integrin) PlA polymorphism in the early development of coronary atherosclerosis[J].Atherosclerosis,2001,154:721-727.
  • 4[4]Lagercrantz J,Bergman M,Lundman P,et al.No evidence that the PLA1/PLA2 polymorphism of platelet glycoprotein Ⅲa is implicated in angiographically characterized coronary atherosclerosis and premature myocardial infarction[J].Blood Coagul Fibrinolysis,2003,14(8):749-753.
  • 5[5]Weiss EJ,Bray PF,Tayback M,et al.A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis[J].N Engl J Med,1996,334:1090-1094.
  • 6[6]Carter AM,Ossei-Gerning N,Wilson IJ,et al.Association of the platelet Pl(A) polymorphism of glycoprotein Ⅱb/Ⅲa and the fibrinogen Bβ 448 polymorphism with myocardial infarction and extent of coronary artery disease[J].Circulation,1997,96(5):1424-1431.
  • 7[7]Ridker PM,Hennekens CH,Sclunitzs C,et al.PLA1/A2 polymorphism of platelet glycoprotein Ⅲa and risks of myocardial infarction,stroke,and venous thrombosis[J].Lancet,1997,349(9049):385-388.
  • 8[8]Walter DH,Schachinger V,Elsner M,et al.Platelet glycoprotein Ⅲa polymorphisms and risk of coronary stent thrombosis[J].Lancet,1997,350:1217-1219.
  • 9[9]Kastrati A,Schornig A,Seyfarth M,et al.PlA polymorphism platelet of glycoprotein Ⅲa and risk of restenosis after coronary stent placement[J].Circulation,1999,99(8):1005-1010.
  • 10[10]Mamotte CD,van Bockxmeer FM,Taylor RR.PLA1/A2 polymorphism of glycoprotein Ⅲa and risk of coronary artery disease and restenosis following coronary angioplasty[J].Am J Cardiol,1998,82:13-16.

同被引文献38

  • 1CUISSET T, CAYLA G, SILVAIN J. Clopidogrel resistance: What's new? [J]. Arch Cardiovasc Dis, 2010, 103 (6/7): 349 - 353.
  • 2NGUYEN T A, DIODATI J G, PHARAND C. Resistance to elopi- dogrel: a review of the evidence[ J]. J Am Coll Cardiol, 2005, 45 (8) : 1157 -1164.
  • 3SEREBRUANY V L, STEINHUBL S R, BERGER P B, et al. Variability in platelet responsiveness to elopidogrel among 544 in- dividuals[J]. J Am Coll Cardiol, 2005,45(2) : 246 -251.
  • 4VERSCHUREN J J, BODEN H, WESSELS J A, et al. Value of platelet phammcogenetics in common clinical practice of patients with ST- segment elevation myocardial infarction[ J]. Int J Cardi- ol, 2013, 167(6) : 2882 -2888.
  • 5TOUSOULIS D, SIASOS G, ZAROMITIDOU M, et al. The im- pact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopi- dogrel[J]. Int J Cardiol, 2013, 168(2) : 1594 - 1596.
  • 6TSANTES A E, IKONOMIDIS I, PAPADAKIS I, et al. Impact of the proton pump inhibitors and CYP2C19 * 2 polymorphism on platelet response to clopidogrel as assessed by four platelet functionassays[J]. ThrombRes, 2013, 132(2): el05-elll.
  • 7PRICE M J, MURRAY S S, ANGIOLILLO D J, et al. Influence of Genetic Polymorphisms on the Effect of High - and Standard - Dose Clopidogrel After Percutaneous Coronary Intervention The GIFT (Genotype Information and Functional Testing) Study[J]. J Am Coll Cardiol, 2012, 59(22) : 1928 -1937.
  • 8KASSIMIS G, DAVLOUROS P, XANTHOPOULOU I, et al. CYP2CI9 * 2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary inter- vention[J]. Thromb Res, 2012, 129(4) : 441 -446.
  • 9NAKATA T, MIYAHARA M, NAKATANI K, et al. Relationship between CYP2C19 loss - of - function polymorphism and platelet re- activities with clopidogrel treatment in Japanese patients undergoing coronary stent implantation [ J ]. Circ J, 2013, 77 (6) : 1436 - 1444.
  • 10JEONG Y H, TANTRY U S, KIM I S, et al. Effect of CYP2C19 *2 and * 3 loss - of - function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin[ J]. Circ Cardiovasc Interv, 2011, 4(6) : 585 -594.

引证文献3

二级引证文献16

心血管病学进展
2006年 第z1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部